Jefferies analyst, Biren Amin, reiterated his Buy rating on shares of Bellicum Pharmaceuticals (NASDAQ: BLCM) and cut his price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE